



Licensing Agreement for Drospirenone

ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo, hereinafter referred to as "ASKA") and Insud Pharma (Head Office: Leon, Spain, hereinafter referred to as "Insud Pharma") have concluded a licensing agreement for the rights to develop and market the oral contraceptive drug, drospirenone as a sole Active Pharmaceutical Ingredient (hereinafter referred to as "Drug") for the territories of Japan and the Republic of Korea.

In Phase III clinical trials conducted by Insud Pharma in the United States and Europe, the Drug was found to be highly effective and safe for female contraception, in accordance with the applicable regulatory guidelines. In the United States, marketing approval of the Drug under the brand name "SLYND[®]" was granted in 2019. In Europe positive outcome for regulatory approval was gained through the European Decentralized Procedure under the brand name "SLINDA[®]" in 2019.

Under the terms of this Agreement, ASKA made an upfront payment for exclusive development and marketing rights for Japan together with sublicense rights for the product in the Republic of Korea. Financial terms for the Agreement were not disclosed.

ASKA is working actively to expand its portfolio of related products as a specialty pharmaceutical leader in the field of women's health. The Company's intention is to make a further contributions to the healthy future for women by bringing this Drug.

[About Insud Pharma]

Insud Pharma is a (<https://www.insudpharma.com/>) pharmaceutical group with its Head Office in Madrid, Spain. Insud Pharma is focusing its efforts on the production of hormonal products for women's health care. By building a distribution network in more than 50 countries around the world, Insud Pharma is meeting the needs of patients and contributing to the overall improvement of medical care.